Takeda Sheds Select Product Assets In Mid-East, Emerging Markets To Acino
In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around 30 selected OTC and Rx products in certain Middle East and other emerging markets to private Swiss group Acino.
You may also be interested in...
Johnson & Johnson previously agreed to acquire TachoSil but terminated the transaction due to regulatory hurdles.
Major new portfolio divestment, along with Deerfield site sale, form part of ongoing effort to pay down Shire-related debt and focus on novel drugs.
Takeda offloads more assets as it focuses on core therapeutic areas and innovative drugs, this time a portfolio of products in emerging markets, with around 500 employees also affected.